Instead, the signs might be more subtle: a persistent feeling of sluggishness, difficulty processing certain foods, or changes in skin clarity
Women over 50 on GLP-1s are dealing with three compounding challenges: age-related muscle loss, menopause-related bone density changes, and the additional muscle loss from the medication itself
Ozempic and other GLP-1 medications also work on the brains dopamine-driven reward circuits, which can be hyperactive in some people and cause excessive cravings
Most patients manage it easily by staying hydrated, eating smaller portions, and not pushing past fullness
However, compounded formulations may contain different inactive ingredients that can cause additional reactions in some people
Transitioning between different weight loss peptides and the dose schedule Researchers who have previously used semaglutide or tirzepatide often want to transition to retatrutide for its superior weight loss efficacy